Inovio PharmaceuticalsNASDAQ: INO

Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in second half of 2024 under U.S. Food and Drug Administration's Accelerated Approval Pathway PLYMOUTH MEETING, Pa. , July 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the appointment of Steven Egge as Chief Commercial Officer.

PLYMOUTH MEETING, Pa. , July 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes.

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) held its Q1 2024 Earnings Conference Call on May 13, 2024 at 4:30 PM ET. Present on the call were Thomas Hong, Jacqueline Shea, Michael Sumner, Mark Twyman, and Peter Kies. Conference call participants included Hartaj Singh, Roy Buchanan, Anish Nikhanj, Roger Song, and Yi Chen. The operator welcomed everyone to the call for the INOVIO First Quarter 2024 Financial Results.

Inovio Pharmaceuticals' top two candidates were unsuccessful, but the company is now pursuing approval for a new product after receiving promising results in clinical trials.

Options bulls are blasting Inovio Pharmaceuticals Inc  (NASDAQ:INO) after Jefferies hiked its price target to $8 from $4.50 on Friday.

The consensus price target hints at a 122.9% upside potential for Inovio (INO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Mark Twyman - Chief Commercial Officer Peter Kies - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Company Roy Buchanan - Citizens Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen and welcome to the INOVIO Fourth Quarter and Year-End 2023 Financial Results Conference Call.

The mean of analysts' price targets for Inovio (INO) points to a 146.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Inovio (INO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.